A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma
https://doi.org/10.21518/2079-701X-2018-10-9-10
Abstract
Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered in Russia, which is used in both the secondand, in the event of high-level PD-L1 expression (≥50%), the first-line therapy. This paper presents a clinical observation of a highly efficient pemribrolizumab treatment of a patient with metastatic adenocarcinoma.
About the Authors
K. K. Laktionov
N.N. Blokhin Russian Cancer Research Centre of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
D. I. Yudin
N.N. Blokhin Russian Cancer Research Centre of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
K. A. Sarantseva
N.N. Blokhin Russian Cancer Research Centre of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
K. P. Laktionov
N.N. Blokhin Russian Cancer Research Centre of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
V. V. Breder
N.N. Blokhin Russian Cancer Research Centre of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
E. V. Reutova
N.N. Blokhin Russian Cancer Research Centre of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Laktionov KK, Sarantseva KA, Breder VV, Okruzhnova MA, Peregudova MV. The role of immuno-oncology in the treatment of non-small cell lung cancer. Zlokachestvennye Opukholi, 2016, 3: 17-24.
2. Sarantseva KA, Laktionova LV, Reutova EV, Chernenko PA, Breder VV. Immunology: creation of an immune response as a leading factor in antitumor protection. Zlokachestvennye Opukholi, 2016, 2: 5-13.
3. Bonomi P. Implications of key trials in advanced nonsmall cell lung cancer. Cancer, 2010, 116: 1155-64.
4. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–smallcell lung cancer. N Engl J Med, 2016, 375(19): 1823-33.
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355: 2524-50.
6. Scagliotti G, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naïve patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol, 2008, 26: 3543-51.
7. Herbst R et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016 Apr 9, 387(10027): 1540-50. doi: 10.1016/S0140-6736(15)01281-7.
8. Shaverdian N, Lisberg A, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol, 2017. Published Online May 24, 2017. doi: 10.1016/S1470-2045(17)30380-7.
9. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 2015, 372: 2018-28.
10. Leighl N, Hellmann M, Hui R et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. Journal of Clinical Oncology, 2017 May, 35(15_suppl): 9011-9011. doi: 10.1200/JCO.2017.35.15_suppl.9011.
11. Chae YK, Pan A, Davis AA, Raparia K et al. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Clin. Lung Cancer., 2016, 17(5): 350-361.
12. Brahmer JR, Rodríguez-AbreuD, Robinson AG, Hui, R et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%. Journal of Thoracic Oncology, 2017 Nov, 12(11): 1793-1794.
Review
For citations:
Laktionov KK, Yudin DI, Sarantseva KA, Laktionov KP, Breder VV, Reutova EV. A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma. Meditsinskiy sovet = Medical Council. 2018;(10):9-10. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-9-10
Views:
765
Email this article 